Light Sciences Oncology, Inc., a privately held company focused on the development
of Light Infusion Technology (Litx) for the treatment of solid tumors, announced
today that it has completed an offering of an additional $32 million of its
Series A Preferred Stock. The completion follows by two months the initial closing
of $35 million of Series A Preferred and brings the total amount of Series A
Preferred to $67 million.